Health Care · Services-Misc Health & Allied Services, NEC

AGL agilon health, inc. SEC Filings & Insider Trading Activity 2026

company
CIK 183109773 filings
Russell 2000

AGL at a glance

agilon health, inc. (AGL, SEC CIK 1831097) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as August 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), agilon health, inc. (AGL) reported revenue of $5.9 billion (down 2.1% from FY2024) and a net loss of $391.3 million.
  • As of December 31, 2025, 25 institutional investment managers tracked by SignalX reported holding agilon health, inc. (AGL) shares worth $114.2 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$5.9B
−2.1% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
25 funds
$114.2M · +1 vs prior quarter
Latest 8-K
Nov 16, 2026
Item 7.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly triggered liquidity risk: Third Amendment requires minimum Total Cash of $50.0 million daily and 100% cash collateralization of letters of credit
  • Most materially updated debt risk: Term-loan maturity extended to February 18, 2028, while revolving commitments fell to $90.0 million
  • Regulatory and compliance risk: CMS risk-adjustment settlements typically arrive 12 to 18 months later, creating revenue reversal exposure
  • Operational risk: Company bears full medical-cost risk for approximately 453,600 Medicare Advantage members
  • Financial concentration risk: Substantially all receivables come from a small number of payors

Management Discussion & Analysis

  • Revenue $1.52B, up 6% YoY from $1.43B, driven by higher PMPM capitation rates and premium yield
  • MSER 88.5% vs 104.0% YoY, with medical services expense down 10% to $1.34B
  • Best performance: profitable geographies, physician incentive expense $54.9M vs $(18.2)M YoY
  • Net income $34.9M vs $(110.2)M; Adjusted EBITDA $63.7M vs $(91.5)M
  • Cash and restricted cash $246.4M, marketable securities $65.4M; nine-month operating cash flow $16.3M vs $(85.2)M

AI summary of the AGL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 16, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Virtual investor event scheduled for November 17, 2026 at 2:00 PM Eastern
  • Presentation webcast available through agilon health’s investor relations website

Item EX-99.1: Item EX-99.1

  • Investor presentation outlines agilon’s technology-enabled Total Care Model, emphasizing clinical pathways, physician engagement and quality programs
  • Platform scale: ~30 markets, ~2,200 primary care physicians, 500K+ Medicare patients and ~$6B managed medical expense as of December 31, 2025
Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release covers agilon health’s third-quarter and nine-month results through September 30, 2026
  • Investors should review Exhibit 99.1 for reported financial performance and management commentary

Item EX-99.1: Item EX-99.1

  • Q3 revenue $1.52B, up 6% YoY despite total platform membership declining 8% to 566,000
  • MSER improved to 88.5% from 104.0%, driving net income $35M versus a $110M loss
Filed Aug 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release announces agilon health financial results for Q2 and first half of fiscal 2026
  • Results cover the three and six months ended June 30, 2026

Item EX-99.1: Item EX-99.1

  • Q2 revenue rose 7% to $1.495B, while net income reached $18M versus a $104M loss, marking a major profitability inflection
  • Medical margin improved to $197M from negative $53M, supported by favorable claims development and medical cost trends

AI summaries of AGL 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for AGL

Don't miss the next AGL filing

  • Alerts as it files. A push when AGL files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut AGL, by share count.
  • Ask anything. An AI agent that reads every AGL filing and answers with sources.

AGL alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Gertsch TimothyFAug 16, 2026$96.90
Zamore DeniseFAug 1, 2026$91.61
Schwaneke Jeffrey A.FJul 1, 2026$111.74
Battaglia SilvanaAJun 2, 2026-
WILLIAMS RONALD AAJun 2, 2026-
Mansukani SharadAJun 2, 2026-
McLoughlin KarenAJun 2, 2026-
MCKENZIE DIANAAJun 2, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$4.3B$6.1B$5.9B
Operating Income-$232.1M-$292.1M-$463.2M
Net Income-$262.6M-$260.2M-$391.3M
Op. Margin-5.4%-4.8%-7.8%
Net Margin-6.1%-4.3%-6.6%
Balance Sheet
Total Assets$1.7B$1.7B$1.3B
Equity-$471.0M$126.7M
ROE--55.2%-308.8%
Cash Flow
Operating CF-$156.2M-$57.8M-$105.8M
CapEx$15.8M$13.3M$13.2M

Source: XBRL data in agilon health, inc. (AGL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q4 2025

Aggregate AGL share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
AGL shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q4 202525$114.2M
Q3 202524$177.5M
Q2 202527$423.8M
Q1 202525$603.9M
Q4 202422$124.7M
Position changes: Q3 2025 → Q4 2025
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 123 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

AGL filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 16, 2026Analysis-
8-KNov 4, 2026Analysis-
10-QNov 4, 2026Analysis
4Aug 18, 2026--
8-KAug 5, 2026Analysis-
10-QAug 5, 2026Analysis
4Aug 4, 2026--
8-KJul 22, 2026Analysis-
4Jul 2, 2026--
4Jun 5, 2026-
4Jun 4, 2026-
4Jun 4, 2026-
4Jun 4, 2026-
4Jun 4, 2026-
4Jun 4, 2026-
4Jun 4, 2026-
8-KJun 3, 2026Analysis
4May 27, 2026-
SC 13GMay 14, 2026-
SC 13GMay 13, 2026-
4May 11, 2026-
8-KMay 6, 2026Analysis
10-QMay 6, 2026Analysis
8-KApr 27, 2026Analysis-
4Apr 16, 2026--

Related Health Care companies

All Health Care →

AGL SEC filings: frequently asked questions

Which institutions hold AGL stock?

As of December 31, 2025, the largest agilon health, inc. (AGL) holders among the 13F filers tracked by SignalX were Morgan Stanley ($37.1 million), BlackRock ($15.6 million), D.E. Shaw & Co ($14.0 million), Goldman Sachs Group ($13.8 million), Vanguard Group Inc ($12.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was AGL's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), agilon health, inc. (AGL) reported revenue of $5.9 billion (down 2.1% from FY2024) and a net loss of $391.3 million. The figures come from the XBRL data in the 10-K.

What did AGL report in its latest 8-K?

agilon health, inc. (AGL) filed an 8-K on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure). Virtual investor event scheduled for November 17, 2026 at 2:00 PM Eastern.

What are the latest AGL SEC filings?

agilon health, inc. (AGL) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on August 18, 2026.

What is AGL's SEC CIK number?

agilon health, inc. (AGL)'s SEC Central Index Key (CIK) is 1831097. EDGAR lists every AGL filing under that number.

Ask anything about AGL

The research agent reads AGL's filings, financials, insider trades and 13F holders, then answers with sources.